You are here
BCRF Investigator Since
Donor Recognition
Area(s) of Focus
Jedd Wolchok, MD, PhD
Chief, Melanoma & Immunotherapeutics Service
Associate Director, Ludwig Center for Cancer Immunotherapy
Attending Physician, Melanoma/Sarcoma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine
New York, New York
Current Research
Seeking strategies to optimize an anti-tumor immune response in breast cancer patients.
Several approaches to improve immunotherapy are being pursued, including a phase I clinical trial for a vaccine in HER2-positive metastatic breast cancer.
These efforts could have a significant impact on advancing immunotherapy to benefit breast cancer patients.
Targeted immunotherapy has re-emerged as an exciting therapeutic option in the arsenal against cancer. Clinical trials of immunotherapy drugs in breast and other cancers have demonstrated a sustained clinical benefit for some patients, but challenges persist in understanding the best approach for each patient and in improving the response to immune-based therapies.
Effective immunization against breast cancer is difficult because breast cancer arises from cells that were once normal, and our bodies have elaborate controls to stop the immune system from attacking our own tissues.
Drs. Wolchok, Merghoub, and Norton have found a way to trick the immune system by using a vaccine from a different species. It works because the immune system recognizes the vaccine as "foreign" and generates an immune response to destroy breast cancer cells as if they were foreign invaders.
A Phase I clinical trial to test the vaccine for safety and efficacy in patients with HER2-positive metastatic breast cancer in currently recruiting patients (ClinicalTrials.gov NCT00393783). In addition, the research team is continuing their studies to optimize the combination of immunotherapy with radiation therapy and to evaluate a combination approach to improve response to immunotherapy.
The hope is that these efforts will inform the design of future clinical trials and advance the use of immunotherapy for breast cancer patients.
Bio
Dr. Wolchok is Chief of the Melanoma and Immunotherapeutics Service, Attending Physician at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Wolchok has helped establish MSKCC as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He also leads the MSKCC Immune Monitoring Facility, a world-renowned full-time core dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapeutic approaches. He is Principal Investigator of numerous ongoing clinical trials at MSKCC in the area of immunotherapy. He supervises an NIH R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical laboratory models. In 2011, Dr. Wolchok established the Immunotherapeutics Clinical Core, a specialized phase 1-2 outpatient unit at MSKCC that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies.
Latest from Jedd Wolchok
Co-Investigators
28 West 44th Street, Suite 609, New York, NY 10036
bcrf@bcrf.org | EIN: 13-3727250